GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
W

Winner Medical Co 300888.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

30.35

-1.27%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥10.95bn

FY2016FY2025

Net income

CN¥768.0m

FY2016FY2025

Free cash flow

CN¥1.02bn

FY2016FY2025

Shareholders' equity

CN¥11.52bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥10.95bnCN¥8.98bnCN¥8.19bnCN¥11.35bnCN¥8.04bnCN¥12.53bnCN¥4.57bnCN¥3.84bnCN¥3.50bnCN¥2.56bn
Gross profitCN¥5.22bnCN¥4.10bnCN¥3.79bnCN¥5.01bnCN¥3.92bnCN¥7.32bnCN¥2.34bnCN¥1.87bnCN¥1.65bnCN¥1.23bn
Research and developmentCN¥410.9mCN¥348.2mCN¥322.1mCN¥487.6mCN¥298.2mCN¥411.4mCN¥155.2mCN¥116.6mCN¥88.6mCN¥61.1m
Operating incomeCN¥1.31bnCN¥914.9mCN¥818.0mCN¥1.98bnCN¥1.48bnCN¥4.53bnCN¥641.8mCN¥530.3mCN¥539.5mCN¥492.1m
Net incomeCN¥768.0mCN¥695.4mCN¥580.4mCN¥1.65bnCN¥1.24bnCN¥3.81bnCN¥546.3mCN¥424.7mCN¥427.2mCN¥409.6m
Diluted earnings per share1.331.180.962.762.086.361.050.730.740.71

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥18.40bnCN¥18.39bnCN¥17.11bnCN¥18.25bnCN¥13.27bnCN¥13.51bnCN¥4.53bnCN¥3.96bnCN¥3.39bnCN¥2.30bn
Cash and short-term investments—CN¥4.33bnCN¥7.56bnCN¥8.91bnCN¥7.40bnCN¥8.29bnCN¥480.8mCN¥403.8mCN¥450.5mCN¥328.5m
Total liabilitiesCN¥6.11bnCN¥6.52bnCN¥5.00bnCN¥6.05bnCN¥2.58bnCN¥3.10bnCN¥1.37bnCN¥1.30bnCN¥1.41bnCN¥647.5m
DebtCN¥50.0mCN¥2.46bnCN¥1.96bnCN¥2.62bnCN¥381.8mCN¥513.9mCN¥254.2mCN¥299.6mCN¥395.0mCN¥60.0m
Shareholders' equityCN¥11.52bnCN¥11.15bnCN¥11.53bnCN¥11.72bnCN¥10.67bnCN¥10.39bnCN¥3.16bnCN¥2.66bnCN¥1.97bnCN¥1.65bn
Shares outstanding578m591m604m597m595m599m522m578m578m578m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.67bnCN¥1.27bnCN¥1.06bnCN¥2.98bnCN¥871.7mCN¥4.77bnCN¥599.8mCN¥467.9mCN¥357.8mCN¥450.1m
Capital spending−CN¥647.9m−CN¥900.9m−CN¥753.1m−CN¥1.20bn−CN¥743.3m−CN¥573.3m−CN¥446.9m−CN¥638.1m−CN¥530.0m−CN¥288.0m
Free cash flowCN¥1.02bnCN¥364.9mCN¥310.3mCN¥1.78bnCN¥128.4mCN¥4.19bnCN¥152.9m−CN¥170.3m−CN¥172.2mCN¥162.2m
Dividends paid−CN¥606.8m−CN¥412.7m−CN¥821.6m−CN¥377.8m−CN¥767.7m−CN¥102.3m−CN¥43.0m−CN¥58.4m−CN¥114.4m−CN¥58.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥2.81bnCN¥2.68bnCN¥3.05bnCN¥2.60bnCN¥2.69bnCN¥2.61bnCN¥2.91bnCN¥2.04bn
Gross profitCN¥1.38bnCN¥1.31bnCN¥1.40bnCN¥1.29bnCN¥1.26bnCN¥1.26bnCN¥1.18bnCN¥1.03bn
Operating incomeCN¥344.4mCN¥391.0mCN¥308.7mCN¥305.7mCN¥318.7mCN¥340.4mCN¥231.4mCN¥210.0m
Net incomeCN¥262.0mCN¥251.5mCN¥36.1mCN¥239.9mCN¥243.4mCN¥248.6mCN¥142.4mCN¥168.8m
Diluted earnings per share0.450.440.060.420.420.430.240.29
Cash from operations———CN¥384.0mCN¥570.0m−CN¥230.0mCN¥778.0mCN¥294.0m
Capital spending−CN¥127.0m−CN¥225.0m−CN¥122.0m−CN¥221.0m−CN¥196.0m−CN¥107.0m−CN¥210.0m−CN¥254.0m
Free cash flow———CN¥163.0mCN¥374.0m−CN¥337.0mCN¥568.0mCN¥40.0m
Total assetsCN¥18.97bnCN¥18.48bnCN¥18.40bnCN¥18.54bnCN¥18.02bnCN¥17.79bnCN¥18.39bnCN¥17.84bn
Cash and short-term investments———CN¥3.85bnCN¥3.66bnCN¥3.53bnCN¥4.33bnCN¥5.71bn
DebtCN¥158.3mCN¥70.0mCN¥50.0mCN¥2.63bnCN¥1.85bnCN¥1.85bnCN¥2.02bnCN¥1.83bn
Shareholders' equityCN¥11.68bnCN¥11.75bnCN¥11.52bnCN¥11.49bnCN¥11.52bnCN¥11.41bnCN¥11.15bnCN¥11.36bn

Financial ratios

Data as of 27 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin47.6%45.6%46.3%44.1%48.7%58.4%—
Operating margin11.9%10.2%10.0%17.4%18.4%36.2%—
Net margin7.0%7.7%7.1%14.5%15.4%30.4%—
Return on equity6.7%6.2%5.0%14.1%11.6%36.7%—
Return on assets4.2%3.8%3.4%9.0%9.3%28.2%—
Free cash flow yield13.6%12.4%10.2%23.8%9.2%30.3%—
Revenue growth22.0%9.7%-27.9%41.2%-35.9%174.0%—
Earnings growth10.4%19.8%-64.8%33.2%-67.5%597.5%—
Current ratio1.74x1.53x2.47x2.21x4.99x4.18x—
Debt to equity0.00x0.18x0.14x0.20x—0.01x0.08x
Equity ratio62.6%60.6%67.4%64.2%80.5%77.0%—
Interest coverage23.71x15.75x12.70x37.01x47.46x844.52x—
R&D as a share of sales3.8%3.9%3.9%4.3%3.7%3.3%—
Buybacks as a share of market value2.2%2.1%-1.1%-0.5%0.7%-14.8%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-1.2%-2.7%19.7%
Operating income-12.9%-22.0%17.9%
Net income-22.5%-27.4%13.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin46.7%45.9%48.9%48.7%
Operating margin11.1%12.7%18.4%17.7%
Net margin7.3%9.4%14.6%14.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings28.535.838.818.528.318.6
Price to sales2.02.82.82.74.45.7

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 25 May 2026.

FY2026FY2025FY2024FY2023FY2022FY2021
Paid in the year0.300.700.901.900.6431.286
  • 7-for-5 split · 2 Jun 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.